Anocca is creating a pipeline of precision T-cell immunotherapies by combining its novel approach to T-cell biology, cutting-edge biotechnologies and integrated software.

Anocca

Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity.
 
Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity. 
 
Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.

European Investment Bank

Swedbank Robur’s Ny Teknik

Nidoco

Ramsbury Invest AB

Harald Mix

Robert Andreen

Swedbank Robur

Mellby Gård AB

Michano

We’re kicking-off 2024 with exciting news! We are pleased to announce that Anocca has secured a GMP manufacturing license from the Swedish Medical Products Agency for our in-house #CellTherapy facility, the largest in the Nordics.

This key regulatory milestone reinforces our commitment to precision #immunotherapy and paves the way for clinical development of Anocca’s #KRAS #TCRT product franchise.

KRAS driver mutations are responsible for aggressive #cancer forms and TCR-T is a therapeutic modality with the potential to transform patient outcomes. 

Manufactured with a next-gen autologous approach, we're set to initiate clinical trials later this year in hard-to-treat solid tumour indications.

🔗Read the full press release here: https://lnkd.in/e5vp4SY3

Anocca is hiring - Are you our Corporate Business Controller?

We are seeking a highly motivated operational Business Controller to join our team. The role allows exposure to all key aspects of financial management and operations. The ideal candidate will have a proven track record of managing financial operations, performing financial analysis, and providing insights to senior management.

The Business Controller will work closely with Anocca’s CFO, Finance organisation and Senior Leadership team and will play a critical role in supporting the company in its transformation from a leading research to clinical stage organisation.

The role is full-time and located at our headquarters in Södertälje.

More information is here: https://lnkd.in/dzBvHW8

Meet our CEO Reagan Jarvis at the J.P. Morgan 42nd Annual Healthcare Conference from January 8-11, 2024.

We’re open to #partnering and #investor meetings to discuss how our deep asset pipeline and novel technologies can help patients.

Anocca’s platform decodes the complexity of T cell biology and enables development of powerful engineered TCR-T #immunotherapies for hard-to-treat solid #tumour indications. 

📧: Schedule a meeting with us at #JPM2024: bd@anocca.com

#biotech #celltherapy #cellandgenetherapy

Our CDO, Mark Farmery will be delivering a key session at Cell & Gene Therapy Manufacturing & Commercialization Europe, from December 4 – 6 in Dublin, Ireland!

📅11:05 – 11:40 | December 5 | Building an Industrialised Platform for the Development and Manufacture of Next-Generation T Cell Therapies

Learn how Anocca leverages its precision biology discovery platform and advanced in-house manufacturing capabilities to decode the complexity of the human immune system and encode and develop powerful engineered TCR-T cell #immunotherapies for hard-to-treat solid #cancer indications.

Connect with Mark there to discuss how we are preparing to take our first highly validated TCR-T product builds into clinical development using the partnering system: https://lnkd.in/ezGrMkME

🔗 Join #CellGene 2023: https://lnkd.in/eeWBzXk

Informa Connect Life Sciences

#biotech #celltherapy #cellandgenetherapy

Developing neoantigen-targeted cell therapies using bioinformatic analyses of patients’ tumor and normal DNA and RNA

Pact Pharma Inc.

An innovative therapeutic biotechnology company developing next-generation immunotherapies that precisely leverage the immune system of each patient.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 13, 2024 10:18 AM	8c7a3f84
public peers	general	Oct 2, 2024 1:59 PM	950e6f04
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 13, 2024 10:18 AM	b96d8cd1
company summary	general
signals	general	Oct 2, 2024 1:59 PM	b24f0d95
crunchbase trigger	general
crunchbase profile	general
li profile	general	Feb 13, 2024 10:18 AM	8e44da9a
translate crunchbase fundingrounds	general
peers	general	Oct 2, 2024 1:59 PM	10b4b72f
news basic	general	Oct 2, 2024 1:59 PM	7ba29f98
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ANOCCA

Anocca